| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.06. | Pasinex Resources Limited: Pasinex Announces Filing of 2023 Annual Financial Results | 81 | GlobeNewswire (Europe) | TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Pasinex Resources Limited (CSE: PSE) (FSE: PNX) (The "Company" or "Pasinex") announces that, further to its news releases dated April 22, 2024, May 13, 2024... ► Artikel lesen | |
| 01.06. | Affimed N.V.: Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort | 284 | GlobeNewswire (Europe) | In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing... ► Artikel lesen | |
| 01.06. | Prospera Energy Inc. Announces 2023 Financial Results | 125 | GlobeNewswire (Europe) | CALGARY, Alberta, June 01, 2024 (GLOBE NEWSWIRE) -- Prospera Energy Inc. ("Prospera" or the "Corporation") (PEI: TSX-V; OF6A: FRA) 2023 was a transformational year for Prospera transforming to horizontal... ► Artikel lesen | |
| 01.06. | Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 123 | GlobeNewswire (Europe) | Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial... ► Artikel lesen | |
| 01.06. | Corbus Pharmaceuticals Holdings, Inc.: SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presente | 93 | GlobeNewswire (Europe) | An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR... ► Artikel lesen | |
| 01.06. | Y-mAbs Therapeutics, Inc.: Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting | 102 | GlobeNewswire (Europe) | NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| 01.06. | Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 | 147 | GlobeNewswire (Europe) | Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose levelsWeekly... ► Artikel lesen | |
| 01.06. | Purple Biotech Ltd.: Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer | 155 | GlobeNewswire (Europe) | 26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC)... ► Artikel lesen | |
| 01.06. | Kymera Therapeutics, Inc.: Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting | 104 | GlobeNewswire (Europe) | KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and... ► Artikel lesen | |
| 01.06. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib | 105 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced... ► Artikel lesen | |
| 01.06. | BioNTech SE: Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) | 926 | GlobeNewswire (Europe) | Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic... ► Artikel lesen | |
| 01.06. | Swiss Properties Invest A/S: Swiss Properties Invest has finalised the acquisition of an attractive commercial property in Koblenz in the Canton of Aargau | 677 | GlobeNewswire (Europe) | Press release/Investor news Copenhagen, 1st of June 2024 Swiss Properties Invest AG has acquired a commercial property in Koblenz in the canton of Aargau. The property has 5'023 m2 usable space... ► Artikel lesen | |
| 01.06. | NIO Inc. Provides May 2024 Delivery Update | 858 | GlobeNewswire (Europe) | NIO delivered 20,544 vehicles in May 2024, increasing by 233.8% year-over-yearNIO delivered 66,217 vehicles year-to-date in 2024, increasing by 51.0% year-over-year Cumulative deliveries of NIO vehicles... ► Artikel lesen | |
| 01.06. | XPeng Inc.: XPENG Announces Vehicle Delivery Results for May 2024 | 897 | GlobeNewswire (Europe) | GUANGZHOU, China, June 01, 2024 (GLOBE NEWSWIRE) -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle ("Smart EV") company, today announced... ► Artikel lesen | |
| 01.06. | Li Auto Inc. May 2024 Delivery Update | 335 | GlobeNewswire (Europe) | BEIJING, June 01, 2024 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (Nasdaq: LI; HKEX: 2015), a leader in China's new energy vehicle market, today announced that the Company delivered... ► Artikel lesen | |
| 01.06. | The Boston Beer Company Statement on Company Sale Speculation | 350 | GlobeNewswire (Europe) | Boston, May 31, 2024 (GLOBE NEWSWIRE) -- The Boston Beer Company, Inc. (NYSE: SAM) is aware of today's Wall Street Journal article on company sale speculation. We do not comment on rumors. We are fully... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 1.682 |
| NEL | 1.667 |
| SUPER MICRO COMPUTER | 1.656 |
| NVIDIA | 1.649 |
| TUI | 1.484 |
| BAYER | 1.336 |
| RHEINMETALL | 1.000 |
| RENK GROUP | 930 |
| PROSIEBENSAT.1 | 912 |
| VOLKSWAGEN | 735 |
| AMAZON | 699 |
| PALANTIR TECHNOLOGIES | 698 |
| TESLA | 687 |
| MICROSTRATEGY | 636 |
| DEUTSCHE BANK | 585 |
| PLUG POWER | 571 |
| BASF | 565 |
| BYD | 557 |
| THYSSENKRUPP | 542 |
| COMMERZBANK | 535 |
| AIXTRON SE | 532 |
| SAP | 507 |
| MERCEDES-BENZ | 506 |
| ALLIANZ | 493 |
| DEUTSCHE TELEKOM | 473 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
